

SESLHDMG/137

Medicine Guideline for the Safe Use of

DANAPAROID***Danaparoid IS A HIGH-RISK MEDICINE*****USE WITH CAUTION AND ENSURE THE DIRECTIONS WITHIN THIS PROTOCOL ARE FOLLOWED CAREFULLY**

Areas where Protocol/Guideline applicable	SESLHD Hospitals
Authorised Prescribers:	Medical Officers. Danaparoid may only be commenced on the advice of a Senior Medical Officer and must be in consultation with haematology
Important Safety Considerations	<p>Danaparoid Sodium</p> <p>Each ampoule contains 750 anti-factor Xa units (approximately 55mg) of danaparoid sodium in 0.6 mL water for injection.</p> <p>Danaparoid should only be used in consultation with Haematology.</p> <ul style="list-style-type: none"> HIT is a complication of heparin therapy with a high rate of thrombotic complications. If the diagnosis is confirmed by a haematologist (or suspected based on assessment using the 4T score) then all forms of heparin (unfractionated and low molecular weight heparins) including heparin flushes, must be discontinued and an alternative anticoagulant started. Thrombocytopenia is not a contraindication to anticoagulation in patients with HIT and platelet transfusions should be avoided unless critical bleeding. If the patient is on warfarin, this should be reversed using vitamin K 5mg IV or oral and not restarted until the platelet count is normal for 2 days. Patients should be screened for asymptomatic proximal DVT which may influence the duration of anticoagulant therapy. Danaparoid does not cross the placenta. Danaparoid has been used in a small number of pregnant patients, the information is still considered to be insufficient to access safety in pregnancy, (category C). There is not data available on danaparoid secretion into breast milk. Seek further advice if considering danaparoid in pregnancy and lactation. Danaparoid is mainly eliminated by renal excretion.
Indication for use	<p>SESLHD formulary approved indication(s):</p> <p>Treatment of heparin-induced thrombocytopenia (HIT) (intravenous infusion): Danaparoid is not registered in Australia for the treatment of heparin-induced thrombocytopenia but is commonly used for this indication. Patient consent should be obtained.</p> <p>Also, in suspected COVID-19 Vaccine Induced Thrombocytopenia with Thrombosis (treatment as per local therapeutic practice for HIT)</p> <p>Non-formulary indication(s) (requiring IPU – individual patient approval):</p> <p>Prevention of VTE (subcutaneous use only) in patients with a history of heparin-induced thrombocytopenia.</p> <p>Prevention of VTE (subcutaneous use only) in patients undergoing general or orthopaedic surgery.</p>

SESLHDMG/137**Medicine Guideline for the Safe Use of****DANAPAROID**

Proposed Place in Therapy	<p>Danaparoid is a non-heparin anticoagulant used to treat HIT. Alternative anticoagulants used to treat HIT include bivalirudin, fondaparinux, argatroban, and lepirudin.</p> <p>Consult haematology regarding choice of therapy for the individual patient and especially where the patient's CrCl is <30mL/min.</p> <p>Argatroban and lepirudin are not currently registered in Australia but are available via the TGA Special Access Scheme.</p>
Contra-indications	<ul style="list-style-type: none"> • Haemorrhagic stroke in acute phase • Uncontrolled active bleeding • Severe haemorrhagic diathesis e.g., haemophilia and idiopathic thrombocytopenic purpura • Hypersensitivity to danaparoid. • Hypersensitivity to sulfite. • A positive <i>in vitro</i> aggregation test in the presence of danaparoid in patients with a history of thrombocytopenia induced by heparin-like anticoagulants. • Severe renal and/or hepatic insufficiency. • Severe hypertension. • Severe gastric or duodenal ulcer unless it is the reason for operating. • Acute bacterial endocarditis. • Diabetic retinopathy.
Precautions	<ul style="list-style-type: none"> • Moderate renal and/or hepatic insufficiency - dosing modification is required (see Dosage - Renal Impairment). An alternative anticoagulant which is not renally cleared is argatroban. • Danaparoid contains sodium sulphite. In asthmatic patients hypersensitive to sulphite, it can result in bronchospasm and/or anaphylactic shock. • Avoid in patients with sulfur allergy. • Do not inject IM – risk of haematoma
Important Drug Interactions	<ul style="list-style-type: none"> • In confirmed or suspected HIT all forms of heparin must be discontinued (unfractionated and low molecular weight) including heparin flushes • Antiplatelet agents e.g., aspirin / clopidogrel / NSAIDs may increase the risk of haemorrhage

SESLHDMG/137

Medicine Guideline for the Safe Use of

DANAPAROID**Dosage****Treatment of HIT**

The administration of danaparoid involves an IV bolus followed by a maintenance infusion. It must be administered by an infusion pump.

Loading dose IV bolus followed by IV infusion below.

- Bolus dose is according to weight:

Weight	Bolus dose	Number of ampoules <i>750 anti-Xa units/0.6 mL injection</i>
< 60 kg	1500 units	2 ampoules
60 – 75 kg	2250 units	3 ampoules
75 – 90 kg	3000 units	4 ampoules
> 90 kg	3750 units	5 ampoules

Note: Haematology may advise omission of bolus if high risk of bleeding or HIT without thrombosis

Initial IV Infusion

9 units/mL infusion	
3 ampoules of 750 units/0.6mL (2250 units) in 250 mL of 5% Glucose	
STEP 1:	
Dose: 400 units/hour	
Rate: 44.4 mL/hour	
Duration: 4 hours**	
STEP 2:	
Dose: 300 units/hour	
Rate: 33.3 mL/hour	
Duration: 4 hours**	
STEP 3:	
patients with GFR > 30 mL/min	patients with GFR < 30 mL/min
Dose: 200 units/hour	Dose: 150 unit /hour
Rate: 22.2 mL/hour	Rate: 16.6 mL/hour
Duration: until first anti-Xa result available, then switch to Maintenance IV infusion	
<i>First anti-Xa assay should be taken after 24 hours from commencement of initial infusion</i>	

**** 2 hourly infusion rate change (instead of 4 hourly) may be more appropriate and safer in the following patients:**

- patients who do not have severe or life-threatening HIT-associated thrombosis.
- patients who are at high risk of bleeding
- patients who have severe renal impairment (GFR<30mL/min)

SESLHDMG/137**Medicine Guideline for the Safe Use of****DANAPAROID****Dosage (cont.)****Maintenance IV infusion**

- The infusion has to be adjusted achieve target anti-Xa level 0.5 – 0.8 units/mL)
- Danaparoid has a plasma elimination half-life for anti-Xa of ~ 25 hours.
- First anti-Xa assay should be taken after 24 hours from commencement of initial infusion.
- Infusion adjusted according to algorithm below.
- Repeat anti-Xa at least once daily whilst on danaparoid.

Suggested algorithm for adjustment of IV infusion.

Anti-Xa level (units/mL)	Dose adjustment	Calculation	Action
<0.5	Increase infusion rate by 20%	New rate x 1.2	Monitor anti-Xa every 24 hours
0.5 – 0.8	GOAL RATE = NO CHANGE	No Change	Monitor anti-Xa every 24 hours
0.8 – 1.0	Decrease infusion rate by 20%	New rate x 0.8	Monitor anti-Xa every 24 hours
>1.0	Decrease infusion rate by 50%	New rate x 0.5	Monitor anti-Xa every 24 hours

In some treatment settings, it may be advisable to aim for a lower anti-Xa level (e.g., 0.3 units/mL) for a patient with a high risk of bleeding. A higher anti-Xa level may be sought (e.g., 0.8-1.0 units/mL) for a patient with life or limb threatening venous or arterial thrombosis, or extra corporeal circulation clotting during continuous renal replacement therapy (CRRT), provided that bleeding is not a problem.

Anti-Xa levels should be rechecked every 24 hours

SESLHDMG/137

Medicine Guideline for the Safe Use of

DANAPAROID**Renal Impairment**Use with caution and consultation with Haematology.

- Consider alternative anticoagulant if CrCl < 30 mL/min especially if there is an increased bleeding risk.
- The elimination half-life is significantly prolonged, and the drug will accumulate. Monitoring of Anti Xa levels and suitable dose reduction is required (consider reduction of the loading dose and maintenance dose by approximately one third in a patient with CrCl < 30 mL/min if there is a risk of bleeding and the patient does not have acute thrombosis).

Dialysis

Patients with **acute HIT** on CRRT (continuous renal replacement therapy - ICU) or Intermittent HD (Haemodialysis) should initially receive the therapeutic intravenous regimen (as described in Dosage section). If the patient does not have a confirmed acute thrombosis, then consider going straight to the maintenance infusion dose of 150-200 units/hour after the IV bolus dose.

Intermittent haemodialysis with a past history of HIT (but **not acute HIT**)

First and second dialysis –

- >55kg give 3750 units IV bolus prior to dialysis.
- <55kg give 2500 units IV bolus prior to dialysis.

Subsequent dialysis sessions are guided by anti-Xa levels and the presence of circuit clotting.

- >55kg and NO significant circuit clotting give 3000 units IV bolus prior to dialysis.
- >55kg and significant clotting of circuit give 3750 units IV bolus prior to dialysis.
- <55kg and NO significant circuit clotting give 2000 units IV bolus prior to dialysis.
- <55kg and significant clotting of circuit give 2500 units IV bolus prior to dialysis.

Danaparoid will accumulate and subsequent dosing must be guided by Anti-Xa levels pre and during each dialysis. Aim for a plasma Anti-Xa level <0.3 units/mL pre-dialysis and 0.5-0.8 units/mL during dialysis.

Patients on dialysis must have their dialysis prescription clearly annotated to avoid inadvertent use of heparin for circuit anticoagulation.

SESLHDMG/137

Medicine Guideline for the Safe Use of

DANAPAROID

Additional considerations	<p><u>Invasive procedures</u></p> <p>Danaparoid has a long half-life and should be stopped at least 24 hours prior to any invasive procedures. It is therefore not the preferred anticoagulant in patients at high bleeding risk or likely to require urgent invasive procedures. Consult haematology for advice in these circumstances.</p> <p><u>Prophylactic administration</u></p> <p>Consider prophylactic dosing only in the following groups:</p> <ul style="list-style-type: none"> patients with a past history of HIT that require DVT prophylaxis (not active HIT) consider in patients with a moderate pre-test probability of HIT in the absence of recent thrombosis, prior to confirmation by laboratory testing, particularly if risk factors for bleeding are present. Administer via subcutaneous injection at a dose of 750 units BD. <p><u>Transition to warfarin</u></p> <p>Danaparoid does not interfere with the INR.</p> <p>Warfarin should not be started until platelet count is normal ($>150 \times 10^9/L$) for 2 days.</p> <p>Warfarin should be initially given in low doses (maximum 5 mg).</p> <p>Warfarin and danaparoid should be overlapped for at least 5 days and at least 2 consecutive INR measurements are within the therapeutic range (2.0-3.0)</p> <p><u>Transition to DOAC</u></p> <p>DOAC should not be started until platelet count is normal ($>150 \times 10^9/L$) for 2 days.</p> <p>Start immediately after ceasing danaparoid, if continuous danaparoid infusion</p> <p>Start in place of the next danaparoid dose, if subcutaneous danaparoid dose</p>
Duration of therapy	<p>HIT with thrombosis.</p> <p>Oral anticoagulation should be continued for a minimum of 3 months in patients with confirmed thrombosis.</p> <p>HIT without thrombosis.</p> <p>Therapeutic danaparoid is continued until platelets have normalised for at least 2 days. Because the risk of thrombosis remains high for 2-4 weeks after treatment is initiated, consideration should be given to continuing anticoagulant therapy with an alternative agent or warfarin for 2-4 weeks unless the patient is judged to be at a high risk of bleeding complications.</p>
Prescribing Instructions	<p>All medication orders for danaparoid must include: - Drug, dose, route and indication, the intended duration of therapy and the word “ANTICOAGULANT” printed clearly.</p> <p>Danaparoid prescription and administration should be documented on the IV fluid chart.</p> <p>Treatment of HIT is an off-label indication in Australia and therefore patient consent for use must be obtained using Form S0199 Consent for Exceptional Use of Medicine</p>

SESLHDMG/137

Medicine Guideline for the Safe Use of

DANAPAROID

Administration Instructions	<p>The administration of danaparoid involves an IV bolus followed by a maintenance infusion. It must be administered by an infusion pump.</p> <p><u>Bolus</u> - Draw up required loading dose according to patient's weight and give as intravenous bolus.</p> <p><u>Maintenance IV infusion</u> – draw up 3 ampoules of 750 units/0.6mL (2250 units) and add to 250 mL of 5% Glucose (final concentration 9 units/mL)</p>
Monitoring requirements	<p>Anti Xa target plasma levels are 0.5 – 0.8 units/mL.</p> <ul style="list-style-type: none"> Factor Xa levels should be checked every 24 hours. Request forms should clearly indicate patient is on danaparoid. The anti-factor Xa activity half-life is 25 hours but biologic half-life due to thrombin generation inhibition activity is approximately 7 hours. For dosage adjustments, see dosage section above
Management of Complications	<ul style="list-style-type: none"> There is no antidote to danaparoid, and it is not removed by dialysis. In the case of haemorrhage cease danaparoid administration immediately. In cases of severe bleeding, plasmapheresis may reduce danaparoid levels. Blood transfusion may be required
Storage requirements	Do not store above 30°C. Do not freeze. Keep the ampoules in the outer carton to protect from light.

SESLHDMG/137

Medicine Guideline for the Safe Use of

DANAPAROID

Basis of Protocol/Guideline:	<ol style="list-style-type: none"> 1. Linkins L A, Dans A L, Moores Lisa K, Bona R, Davidson B L, Schulman S, Crowther M. Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Supplement) e495S-e530S. doi:10.1378/chest.11-2303 2. Shenk J F, Pindur G, Stephan B, Morsdrop S, Mertzlufft F, Kroll H, On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin Induced Thrombocytopenia. Clin Appl Thrombosis/haemostasis. 2003; 9 (1): 25 -32. 3. Gallus A, Clinical protocol/guideline. Government of South Australia. Southern Adelaide Local Health Network. 4. Fanchini M. Heparin –induced thrombocytopenia: an update. Thromb Journal.2005;3;14 doi:10.1186/1477-9560-3-14 5. Kelly L, Morgan B, Danaparoid, Critical Care Trauma Centre, London Health care Sciences Centre Canada. Protocol. 2006. 6. Magnani H, Wester JP. Is Danaparoid Anticoagulation Suitable for Patients with HIT and ARF Requiring CVVRT? An Analysis of Case Reports. Netherland Journal of Critical Care. 2004; 8(4):293 – 301.https://www.omicsonline.org/scientific-reports/2155-9864-SR-423.pdf 7. Warkentin, T., & Greinacher, A. (2012) (5th ed., pp.466-488). <i>Heparin-induced thrombocytopenia</i>. Boca Raton: CRC Press. 8. Joseph, J., Rabbolini, D., Enjeti, A., Favaloro, E., Kopp, M.-C., McRae, S., . . . Chong, B. (2019). Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group. Medical Journal of Australia, 210(11), 509-516. doi:10.5694/mja2.50213 9. MIMS Online. Orgaran. Last updated 01 October 2024 10. Australian Medicines Handbook. Danaparoid. January 2025 11. Australian Injectable Drug Handbook, 9th Edition. Danaparoid. Last updated 16 June 2025. 12. UpToDate. Danaparoid: Drug Information. [Accessed 22 August 2023]
Groups consulted in development of this guideline	Haematology Clinical Director and Haematology Department St George Blood Transfusion Committee SESLHD Pharmacists

SESLHDMG/137
Medicine Guideline for the Safe Use of
DANAPAROID



AUTHORISATION	
Author (Name)	Samantha Connelly (CNS2 Blood and Blood Products) Sarah Jones (CNC Intensive Care Services) Dr Amanda Hugman (Haematologist) Professor Beng Chong (Haematologist) Tim Brighton (Haematologist) Suman Adhikiri (Senior Pharmacist)
Department	Haematology, SGH
Position Responsible (for ongoing maintenance of Protocol)	Dr Amanda Hugman Amanda.Hugman@health.nsw.gov.au
GOVERNANCE	
Enactment date <i>Reviewed</i> (Version 2) <i>Reviewed</i> (Version 3) <i>Reviewed</i> (Version 3)	December 2017 September 2021 August 2023 July 2025
Expiry date:	August 2027
Ratification date by SESLHD DTC	7 August 2025
Chairperson, DTC	Dr John Shephard
Version Number	3.0